Combining targeted therapy with a stroma-modulating agent for pancreatic cancer
Official title: Combination of tumor targeted therapy with stroma modulating agent for PDAC
Funded at St. John's University · NIH-11083663 · Data updated 2026-11-12
This study is exploring a new way to treat pancreatic cancer by using a special combination of drugs that not only attack the cancer cells but also help the surrounding tissue, making it easier for the medicine to work better, and patients may have the chance to participate in testing how safe and effective this treatment is.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | St. John's University NIH-funded |
| Lab location | 1 site (Queens, United States) |
| Project start | June 12, 2023 |
| Project end | May 31, 2027 |
| Funding year | 2025 |
| Award (this year) | $164,000 |
| NIH project number | 5R16GM145556-03 |
| Project ID | NIH-11083663 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with pancreatic ductal adenocarcinoma who have not responded well to standard treatments.
✕Less likely to help
Patients with other types of cancer or those who have already exhausted all treatment options may not benefit from this research.
What this research studies
This research investigates a new treatment approach for pancreatic ductal adenocarcinoma (PDAC), a highly aggressive form of cancer. The study aims to enhance the effectiveness of anticancer drugs by targeting both the tumor cells and the surrounding stroma, which often hinders drug delivery. By using a specific inhibitor to modify the tumor microenvironment and a novel class of anticancer molecules called PROTACs, the research seeks to improve drug uptake and overcome resistance to existing therapies. Patients may be involved in trials assessing the safety and efficacy of these combined treatments.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for pancreatic cancer, potentially improving survival rates and quality of life for patients.
How similar studies have gone: While the approach of targeting both tumor cells and the stroma is innovative, preliminary studies have shown promise in similar strategies, indicating potential for success.
Where this research is happening
-
St. John's University
Queens, United States Active
Researchers
- Principal investigator: Patel, Ketankumar D. — St. John's University
- Study coordinator: Patel, Ketankumar D.
Related research
Other NIH-funded projects on the same topics.
-
Combination therapy targeting tumor and surrounding stroma in pancreatic cancer
Aims to improve treatment for pancreatic cancer by delivering a targeted therapy together with a agent that changes the tumor environment to help drugs work better.
-
Integrative histo-genomic analysis to guide cancer risk and targeted therapies with interpretable AI
Researchers are developing an advanced AI-powered approach to map genetic and cellular patterns across breast and cervical cancers to help tailor treatments.
-
Targeted therapy for AML using DHODH inhibitors to boost differentiation and immune response
Aims to help adults with acute myeloid leukemia by using a special drug approach that makes cancer cells act more like normal blood cells and supports the immune system.
-
Targeting epigenomic regulators to assault pancreatic cancer replication stress
This research tests a new way to treat pancreatic cancer by blocking key epigenetic regulators during DNA replication to make cancer cells less able to cope with replication stress.
-
Adipome biomarkers in obese TNBC mice for targeted therapy
A study in mice explores how fat-derived particles called adipomes influence an aggressive breast cancer type, with the goal of guiding personalized therapies.
-
Enhancing HER2-targeted therapy for resistant breast cancer
This grant explores new ways to overcome resistance to HER2-targeted therapy in people with HER2-positive breast cancer.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.